Researchers enhance sarcopenia treatment by analyzing gut bacteria and genetics Personalized strategies are essential for ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

Publication of SARA-INT Phase II results for BIO101Confirmation of Phase 3 readinessParis, France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

Skeletal Muscle Index decreased as Metabolic Score for Visceral Fat increased, which was most significant among those with diabetes and obesity.

The "Sarcopenia - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers an in-depth analysis of the current developments and future prospects in the ...

The presentation included positive Phase 2a clinical data showing decreases of biomarkers associated with TNF-α activation in elderly patients with sarcopenia. The Company’s recently initiated ...

While a gradual loss in muscle strength is a natural part of aging, for many older adults it's more than just feeling a little weaker. Sarcopenia -- a condition affecting nearly half of adults over 80 ...

Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which is a serious medical ...